Fuan Pharmaceutical's wholly-owned subsidiary Tianheng Pharmaceutical recently obtained a drug registration certificate for Bromhexine Hydrochloride Injection from the National Medical Products Administration. The drug is registered as a chemical drug Category 3, with a specification of 2ml:4mg, and is indicated for patients with chronic bronchitis and other respiratory diseases who have difficulty expectorating viscous sputum when oral administration is challenging. To date, a total of 30 companies have passed or are deemed to have passed the consistency evaluation for this drug. In the first quarter of 2026, Fuan Pharmaceutical achieved revenue of 407 million yuan and a net profit attributable to the parent company of 54.92 million yuan.
Fuan Pharmaceutical Group CoSubsidiary obtained drug registration certificate for Bromhexine Hydrochloride Injection, enabling market entry.
Obtained drug registration certificate for Bromhexine Hydrochloride Injection from NMPA.